Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #19 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 427,010 | 143.5 | 13.7% | 7.6% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 244,125 | 83.0 | 15.3% | 57.8% | 0.33% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 161,506 | 77.7 | 12.2% | 35.3% | 0.80% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 113,616 | 32.6 | 17.3% | 14.5% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 107,888 | 35.1 | 11.2% | -11.7% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,505 | 122.0 | 17.1% | 128.4% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 102,382 | 46.9 | 11.7% | 0.9% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 100,411 | 150.9 | 10.9% | -3.7% | — | 62 | 33 | 71 |
| Ajanta Pharma Limited (this stock) | 43,553 | 43.2 | 23.3% | 43.4% | — | 90 | 0 | 86 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 1,626 | 447 | 334 | ₹ |
| March 31, 2026 | 1,422 | 347 | 267 | ₹ |
| Dec. 31, 2025 | 1,375 | 359 | 274 | ₹ |
| Sept. 30, 2025 | 1,354 | 341 | 260 | ₹ |
| June 30, 2025 | 1,303 | 331 | 255 | ₹ |
| March 31, 2025 | 1,170 | 269 | 225 | ₹ |
| Dec. 31, 2024 | 1,146 | 307 | 233 | ₹ |
| Sept. 30, 2024 | 1,187 | 290 | 216 | ₹ |
| June 30, 2024 | 1,145 | 322 | 246 | ₹ |
| March 31, 2024 | 1,054 | 278 | 203 | ₹ |
| Dec. 31, 2023 | 1,105 | 291 | 210 | ₹ |
| Sept. 30, 2023 | 1,028 | 276 | 195 | ₹ |
| June 30, 2023 | 1,021 | 269 | 208 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 5,453 | 1,378 | 1,056 |
| March 31, 2025 | 4,648 | 1,189 | 920 |
| March 31, 2024 | 4,209 | 1,114 | 816 |
| March 31, 2023 | 3,743 | 745 | 588 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 529 | -429 | -168 | 365 | 164 |
| March 31, 2025 | 1,157 | -377 | -733 | 318 | 839 |
| March 31, 2024 | 785 | 65 | -1,051 | 152 | 633 |
| March 31, 2023 | 792 | -560 | -108 | 174 | 617 |
| March 31, 2022 | 562 | -74 | -460 | 149 | 413 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 6,155 | 4,527 | 4,502 | 212 | 0 | 3,735 | 1,416 | 103 | 1,726 | 939 |
| March 31, 2025 | 5,015 | 3,790 | 3,765 | 3 | 0 | 2,830 | 996 | 175 | 1,625 | 904 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
